Evopoint Biosciences Co, Ltd

Performance in the 2026 Benchmark*

Low-performing. Evopoint’s sole pipeline project, funobactam, targets ‘high’ and ‘critical’ priority pathogens. However, it is not classified as innovative, as it does not meet any of WHO’s innovation criteria – or the Benchmark’s ‘other’ innovation criterion that assesses real-world utility in LMICs. In addition, it can strengthen its access and stewardship planning, with yet no plan in place for funobactam. 

_{^{* For the 2026 AMR Benchmark, Evopoint declined to submit data.}} 

Opportunities for Evopoint

Work with partners and utilise existing guidance to develop access and stewardship plans for funobactam. Evopoint's sole pipeline candidate, funobactum (XNW4107), targets several WHO-listed bacterial priority pathogens – namely Gram-negative carbapenem-resistant pathogens – and it is currently under regulatory review in China for hospital-acquired and ventilation-associated bacterial pneumonia. The company does not report an access or stewardship plan for funobactam. When it expands the access and stewardship plan it can utilise the Stewardship & Access Plan (SAP) Development Guide and work with partners to strengthen its approach, focusing on regions with high levels of resistance and significant clinical need, particularly in settings with limited or no treatment options. 

Sales & Operations

• Therapeutic areas: Anti-infectives, oncology   

• Financial stage: Private (Series E financing of RMB 700mn completed in February 2024; IPO filing submitted to China Securities Regulatory Commission in July 2025) 

• Products on the market: None 

• Commercial partners: Evopoint has an exclusive licensing agreement with Astellas for XNW27011, an antibody-drug conjugate in solid tumours, with Astellas holding worldwide rights except in select Asian markets. EVER001 (XNW1011/SN1011), a Bruton’s tyrosine kinase inhibitor for renal diseases, has been licensed to Everest Medicines with global rights for development, manufacturing and commercialisation. 

• Funding partners: Evopoint has received funding from Apricot Capital, CICC Capital, GIC, Guoxin Investment, Lepu Medical, Loyal Valley Capital, Oceanpine Capital and Tencent Investment, among other investors. 

Sample of pipeline assessed by the Benchmark

Pipeline for diseases in scope

Research & Development

One antibacterial candidate targeting critical and high-priority pathogens undergoing regulatory review. Evopoint has 1 project in its pipeline targeting pathogens in scope. Its candidate, funobactam (XNW4107), an antibacterial medicine, is currently undergoing regulatory review in China for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). It targets 3 priority pathogens, including those defined as ‘critical’ and ‘high’ on WHO’s bacterial priority pathogen list: carbapenem-resistant Acinetobacter baumanii (CRAB), carbapenem-resistant Enterobacterales and carbapenem-resistant Pseudomonas aeruginosa. Funobactam does not meet any of WHO's innovation criteria. The company did not report an active in-house discovery programme.   

No access or stewardship plans in place for its sole late-stage project. Evopoint has not yet developed an access or stewardship plan for its sole late-stage project, Funobactam, nor are clinical trials ongoing in any countries in scope.